Pathway Studio Plant is a part of Elsevier's Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow; including ScienceDirect, Scopus, TargetInsights, Reaxys, Reaxys Medicinal Chemistry, PharmaPendium, QUOSA and Embase.
For further information go to elsevier.com/pathway-studio
About Pathway Studio
A robust informatics solution, Pathway Studio provides scientists with an unparalleled knowledge base of molecular interactions drawn from literature-based evidence. Integrated data mining, analytical, and visualization capabilities rapidly connect relevant biological relationships and interpret experimental data. Presented in a visual context, results can be used to define and test in silico-based hypotheses across a wide range of disciplines, increasing efficiency and research confidence. For more information, got to: http://www.elsevier.com/online-tools/pathway-studioAbout Elsevier Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively. A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). Media contact Liz Griffioen Elsevier +31-20-485-2247 L.email@example.com SOURCE Elsevier
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts